Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals is a pioneering commercial-stage biotechnology company specializing in the discovery and development of RNA-targeted medicines. As the inventor of antisense oligonucleotide (ASO) technology, Ionis has established itself as a leader in RNA therapeutics with a focus on treating serious genetic and rare diseases. The company employs advanced technology platforms including antisense inhibitors, RNAi therapeutics, and CRISPR-based approaches to precisely target and interact with RNA and DNA. With a 35-year history (founded in 1989), Ionis has transitioned from a research-focused biotech to a fully integrated, commercial-stage pharmaceutical company with multiple approved medicines and an industry-leading pipeline of investigational therapeutics targeting neurology, cardiology, and rare genetic diseases.